-
DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19
DARE-19 Principal Investigator Mikhail Kosiborod, MD, will provide the first look at a subgroup analysis of type 2 diabetes patients who are at higher risk for developing serious complications from COVID-19.
-
Frontline professionals will discuss interplay between COVID-19 and diabetes
The diabetes community moved quickly to understand and counter the deadly dynamics of COVID-19 and hyperglycemia. Alberto Coppelli, MD, and Francisco J. Pasquel, MD, MPH, provide a view from the frontlines.
-
Experts will explain how viruses, including COVID-19, affect pediatric diabetes risk
“The relationship between viruses, genetic background, and the immune system are all involved in this autoimmune process that leads to disease,” explains epidemiologist Kendra Vehik, PhD, MPH.
-
Questions of readiness feed precision nutrition debate
Paul W. Franks, PhD, and Kevin D. Hall, PhD, will present opposing viewpoints about whether the hype about precision nutrition outweighs the science during a debate on the final day of the Scientific Sessions.
-
Long-standing barriers complicate patient care despite effective DKD treatment options
Maryam Afkarian, MD, PhD, will explore some of the challenges to the practical application of tools to manage diabetes and kidney disease.
-
Experts to weigh starting SGLT2 inhibitors and GLP-1 receptor agonists in the hospital
Jennifer Green, MD, will discuss some of the factors that may give clinicians second thoughts about initiating the two drug classes.
-
High dimensional data moves from bench to bedside with focus on individualized care
Manoj Bhasin, PhD, MS, will unveil some of the latest developments in multi-dimensional and spatial single-cell omics.
-
81st Scientific Sessions will showcase the latest basic, translational, and clinical science
Dana Dabelea, MD, PhD, Chair of the 81st Scientific Sessions Meeting Planning Committee, gives an overview of the science and opportunities for live interaction at this year’s virtual meeting taking place June 25–29.
-
Results from head-to-head trial of four type 2 diabetes agents to be presented
“We hope to give a comprehensive, comparative view of which drugs do what and in which people,” said GRADE Principal Investigator David Nathan, MD.
-
SURPASS clinical trials may lead to the next chapter in incretin-based therapies
New, detailed results of the first Phase 3 SURPASS clinical trials involving tirzepatide will be presented in a dedicated symposium. “The glucose-lowering and weight reductions of this dual incretin receptor agonist are unprecedented,” said Julio Rosenstock, MD.